On March 28, 2017, the U.S. Food and Drug Administration (FDA) approved the use of Ocrevus (ocrelizumab) in treating multiple sclerosis (MS). Ocrevus is a new biologic and is the first drug approved by the FDA to treat...more
Anticipation by inherent disclosure requires that a single prior art reference necessarily includes the unstated limitation. The unpredictable nature of biological processes means that winning summary judgment of invalidity...more
1/19/2017
/ Anticipation ,
Appeals ,
Biologics ,
Biotechnology ,
Expert Testimony ,
Inherent Disclosure Doctrine ,
Patent Invalidity ,
Patent Litigation ,
Patents ,
Prior Art ,
Summary Judgment ,
Vacated